Supplementary Materials

Supplementary Material for:

Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma

Elisa Oricchio,* Natalya Katanayeva, Maria Christine Donaldson, Stephanie Sungalee, Joyce P. Pasion, Wendy Béguelin, Elena Battistello, Viraj R. Sanghvi, Man Jiang, Yanwen Jiang, Matt Teater, Anita Parmigiani, Andrei V. Budanov, Fong Chun Chan, Sohrab P. Shah, Robert Kridel, Ari M. Melnick, Giovanni Ciriello, Hans-Guido Wendel

*Corresponding author. Email: elisa.oricchio{at}

Published 28 June 2017, Sci. Transl. Med. 9, eaak9969 (2017)
DOI: 10.1126/scitranslmed.aak9969

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Genomic analysis of frequently altered regions in 260 FLs.
  • Fig. S2. Characterization of vavBcl2 lymphoma mouse model.
  • Fig. S3. Characterization of epigenetics and expression of SESTRIN1, SESTRIN2, and SESTRIN3 in FL and DLBCL.
  • Fig. S4. Regulation of mTOR signaling by SESTRIN1 in lymphoma.
  • References (3743)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel format). Copy number analysis of 260 indolent FL samples.
  • Table S2 (Microsoft Excel format). Quantification of homozygous and heterozygous deletions on Chr. 6q in 260 FL.
  • Table S3 (Microsoft Excel format). Analysis of focal deletions on Chr. 6q.
  • Table S4 (Microsoft Excel format). shRNA screen analysis.
  • Table S5 (Microsoft Excel format). Sestrin1 expression in EZH2WT or EZH2Y641X GCB-DLBCL patient samples.
  • Table S6 (Microsoft Excel format). Differential expression analysis of genes on Chr. 6q in EZH2WT or EZH2Y641X cell lines.
  • Table S7 (Microsoft Excel format). Differential expression analysis of cell lines treated with the EZH2 inhibitor (GSK126) or DMSO.
  • Table S8 (Microsoft Excel format). List of lymphoma cell lines with relevant genomic lesions.

[Download Tables S1 to S8]